Fruquintinib Plus Paclitaxel Under Study as Second-Line Treatment of Gastroesophageal Cancer – The ASCO Post
The combination of the small molecule inhibitor of VEGFR fruquintinib and the chemotherapy paclitaxel presents a potential new second-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to data presented during the ASCO Plenary Series: Februar y 2024 Session. 1 Results of the phase III FRUTIGA study (conducted in China) showed significantly improved progression-free survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma